Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage ...

Air pollution in Hanoi has become a major public health issue, as increasing cases of respiratory illnesses prompt healthcare ...

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples that can be obtained from a cheek swab or blood test, they can improve identification of people ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

belief that Ohtuvayre's bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm." The encouraging sales figures come at a time when treatment options ...

A potentially benefial bacterial strain and its functional component may be developed and used as alternative agents for COPD prevention or treatment. Data are available on reasonable request. All ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.